Yes, the mice did not have AD. This is a basic misunderstanding for biotech neophytes, and puzzling for anyone with even just undergrad biology training.
Likewise the extrapolation of a ligand's PK in mice to a different mammal based on their longevities. The receptor is conserved, so the molecular binding profile would be the same. For no reason should any aspect of it be "interpreted" to be ~36 times longer or greater in, say, humans, nor its therapeutic effects. That's profoundly inaccurate, irrational, and unscientific.
This paper has been discussed here before. It has great explanations for the complexity of the S1 receptor and the major known ligands, particularly around its activation. First paragraph of page 9 is striking, but all of it should be read. S1 has a lot of potential 'drugability'. But it may be tricky to activate therapeutically and predictably. Clinical trials will be particularly helpful here.